Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

By Kelly Bilodeau • Oct. 25, 2023

Pfizer’s new shot approval adds to a growing vaccine prowess

Pfizer brought in a new approval for a five-in-one shot for meningococcal disease, and the company has built a sizable vaccine business over time.

By Michael Gibney • Oct. 24, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

An ‘inverse vaccine’ takes aim at autoimmune diseases

Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

By Kelly Bilodeau • Oct. 23, 2023

From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

By Kelly Bilodeau • Oct. 17, 2023

The top biopharma conferences in 2024

A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

By Ned Pagliarulo • Oct. 16, 2023

Has the science of anti-aging caught up with the dream of a longer life?

Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

By Kelly Bilodeau • Oct. 16, 2023

PharmaVoice 100s: Rare disease warriors

Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

By Michael Gibney • Oct. 16, 2023

Branded: The trademarks pharma leaders look up to

What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

By PharmaVoice Staff • Oct. 13, 2023

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

By Michael Gibney • Oct. 12, 2023

A decade later, biotech’s CRISPR revolution is still going strong

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023

To close the pediatric innovation gap, this biotech has to think differently

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

By Alexandra Pecci • Oct. 11, 2023

5 minutes with — IDEA Pharma’s Mike Rea

The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

By Meagan Parrish • Oct. 11, 2023

Research in space yields clues about boosting bone health on Earth

A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.

By Kelly Bilodeau • Oct. 10, 2023

Google bets on AI in the life sciences as ‘technology for a purpose’

A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

By Alexandra Pecci • Oct. 10, 2023

A biotech ‘tuning’ the genome for a potentially safer gene therapy

Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

By Kelly Bilodeau • Oct. 9, 2023

Key upcoming events for pharma execs

Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

By Meagan Parrish • Oct. 6, 2023

FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

By Michael Gibney • Oct. 5, 2023

Where have all the unicorns gone? A look at 4 billion-dollar biotechs

Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.

By Alexandra Pecci • Oct. 3, 2023

5 FDA decisions to watch in the fourth quarter

The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.

By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023

The ALS therapy keeping the human pig heart transplant pumping

Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.

By Kelly Bilodeau • Oct. 2, 2023

3 recent FDA adcomm rejections — and why they matter

Decisions that could spell doom for drugs in development and already on the shelves.

By Meagan Parrish • Sept. 29, 2023

Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’

The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.

By Alexandra Pecci • Sept. 26, 2023

Three years after an FDA rejection, DBV sees a path for its peanut patch

Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

By Karissa Waddick • Sept. 22, 2023

What happened to ivermectin?

The saga of the anti-parasitic drug continues.

By Alexandra Pecci • Sept. 20, 2023

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023